CDC: PCV10 Reduces Carriage Rates Among Children

The 10-valent pneumococcal conjugate vaccine (PCV10) that Kenya introduced in 2011 has caused a decline in cases of both PCV10-type (VT) and penicillin nonsusceptible (intermediate or resistant) pneumococci (PNSP), according to new data presented at IDWeek 2018.

The study, authored by Miwako Kobayashi, MD, and colleagues, was presented on Friday, October 5, at IDWeek 2018 in San Francisco.

IF YOU LIKE THIS, READ MORE...

WHO: Ebola Vaccine is Resisted in the Congo

Pediatric Immunization Schedule 2018

Between 2009 and 2013, the researchers performed annual cross-sectional pneumococcal carriage surveys for 2962 Kenyans younger than age 5 years and 2028 HIV positive adults. In their analysis, the researchers examined the impact of the newly implemented 3 doses at 6, 10, and 14 weeks on pneumococcal carriage and antibiotic susceptibility for both children and adults with HIV.

The surveys’ results showed that VT carriage had declined by 52% to 60% in children aged 1 to 4 years, by 60% in children younger than a 1 year, and by 76% in HIV positive adults. PNSP carriage had declined from 32.8% to 22.3% in HIV positive adults but did not change in children younger than 5 years.

“The infant PCV10 program was associated with declines in VT carriage among [children younger than 5 years] and HIV+ adults, and declines in PNSP carriage among HIV+ adults,” the researchers wrote. “However, VT carriage remained >10% among [children younger than 5 years] two years post-PCV10 introduction.”

—Colleen Murphy

Reference:

Kobayashi M, Kim L, Bigogo G, et al. Impact of 10-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage and antibiotic susceptibility patterns among children aged <5 years and adults with HIV infection, Kenya 2009-2013. Paper presented at: IDWeek 2018; October 3-7, 2018; San Francisco, CA. https://idsa.confex.com/idsa/2018/webprogram/Paper72367.html. Accessed October 16, 2018.